Here we go again...

"Yes a far cry from 17% and those resaults have been matched to grade. CYP have given fauls information."

Treatment and unmet needs in steroid-refractory acute graft-versus-host disease

https://www.nature.com/articles/s41375-020-0804-2

[...]

Steroid-refractory aGVHD

The recommended first-line treatment for aGVHD is systemic steroid therapy [7,30]; however, ~35–50% of patients become refractory to steroid therapy [10,31]. SR-aGVHD can be defined as a clear progression after 3–5 days of treatment or no response after 5–7 days of treatment; [6,7] however, the exact definition can vary by center. SR-aGVHD is associated with a high mortality risk [8,10,32,33]. The weighted average 6-month survival estimate across 25 studies was 49%; [8] another study reported an estimated 2-year survival rate of 17% [10]. Patients with SR-aGVHD also had higher nonrelapse mortality at 18 months (63% vs 34%) and 2 years (65% vs 35%) than patients who responded to steroid treatment [10]. Likewise, infection-related mortality was high in patients with SR-aGVHD. In a retrospective study of 127 adults, the 1-year incidence of bacterial, viral, and fungal infections was 74%, 65%, and 14%, respectively. Infection-related mortality and overall survival (OS) at 4 years were 46% and 15%, respectively. Bacterial infection was the most common infection leading to death [32].

[...]

Here's the study:

https://www.hindawi.com/journals/ah/2011/601953/